Vivos Therapeutics, Inc. 是一家医疗技术公司,致力于为患有睡眠呼吸障碍(如轻至中度阻塞性睡眠呼吸暂停(OSA))的患者开发和商业化治疗替代方案。公司总部位于科罗拉多州高地牧场。
财务指标
营业收入
2026-06-30
$515.3万
2026-03-31
$514.1万
2025-12-31
$382.4万
2025-09-30
$678.3万
营业支出
2026-06-30
$777.8万
2026-03-31
$922万
2025-12-31
$1020.6万
2025-09-30
$867.1万
净利润
2026-06-30
-$548.1万
2026-03-31
-$775.1万
2025-12-31
-$695.4万
2025-09-30
-$540万
净利润率
2026-06-30
-106.36%
2026-03-31
-150.76%
2025-12-31
-181.85%
2025-09-30
-79.61%
每股收益
2026-06-30
$-0.31
2026-03-31
$-0.52
2025-12-31
$-0.58
2025-09-30
$-0.49
息税折旧摊销前利润
2026-06-30
-$391.2万
2026-03-31
-$729.7万
2025-12-31
-$594万
2025-09-30
-$501.6万
有效税率
2026-06-30
0.76%
2026-03-31
0.89%
2025-12-31
--
2025-09-30
--
项目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
营业收入
$515.3万
$514.1万
$382.4万
$678.3万
营业支出
$777.8万
$922万
$1020.6万
$867.1万
净利润
-$548.1万
-$775.1万
-$695.4万
-$540万
净利润率
-106.36%
-150.76%
-181.85%
-79.61%
每股收益
$-0.31
$-0.52
$-0.58
$-0.49
息税折旧摊销前利润
-$391.2万
-$729.7万
-$594万
-$501.6万
有效税率
0.76%
0.89%
--
--
常见问题
VVOS represents Vivos Therapeutics, a medical technology company focused on developing and commercializing innovative treatments for obstructive sleep apnea and other sleep-related breathing disorders. The company's proprietary systems are designed as alternatives to traditional continuous positive airway pressure (CPAP) machines for certain patients. VVOS also provides education and training to healthcare providers. Its products and services aim to address a large patient population seeking non-invasive options. For precise details on current products and operations, refer to the latest VVOS filings or the company's official disclosures.
Recent performance of VVOS stock can vary significantly due to news, market conditions, and company-specific developments. To see the latest price changes over different time frames, such as daily, weekly, or year-to-date, check the performance section on this page. The displayed data reflects the most current available information. Historical price trends and percentage moves are also typically shown to help contextualize recent activity.
The 52-week range shows the lowest and highest prices at which VVOS has traded over the past year. This metric helps investors understand the stock's price volatility and where the current price sits relative to its annual extremes. For the most up-to-date 52-week range, please refer to the data displayed on this page. It is a useful reference for gauging historical price boundaries, but it does not predict future movements.
Evaluating VVOS's valuation involves examining metrics such as price-to-sales, price-to-book, and enterprise value, especially if the company is not yet profitable. Comparing these ratios to industry peers and the company's own historical averages can provide context. Because VVOS operates in a specialized sector, understanding its revenue growth, cash burn, and path to profitability is also important. For current valuation metrics, see the data shown on this page and review VVOS's financial statements for fundamental analysis.
To buy VVOS stock, you need a brokerage account that offers access to U.S. equity markets. Once your account is funded, you can place a buy order through your broker's platform, specifying the number of shares and order type, such as market or limit. VVOS is listed on a major U.S. exchange, so it is widely available through most online brokers. Ensure you understand any commissions or fees. The actual execution price will depend on market conditions at the time of your order.
Investing in VVOS carries risks typical of small-cap medical technology companies, including regulatory hurdles, clinical trial outcomes, reimbursement challenges, and competition from established sleep apnea treatments. The company's financial performance may be affected by its ability to commercialize products, manage cash resources, and achieve profitability. Market sentiment and liquidity can also lead to price volatility. For a comprehensive list of risk factors, review VVOS's most recent annual report (Form 10-K) and other SEC filings.